Clinicopathological Correlations, Treatment Response, and Predictors of Outcomes in Childhood Lupus Nephritis in China
International Journal of Rheumatic Diseases · 2026-07 · 29 (7)
DOI: 10.1111/1756-185x.70774 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 18.07.2026. Verfasst von Bai-Xu Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. Hauptthemen laut MEDLINE: Lupus Nephritis, Immunosuppressive Agents, Kidney, Glucocorticoids. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
To investigate clinicopathological correlations, treatment responses, and predictors of outcomes in childhood lupus nephritis (cLN).
Methods
Retrospective cohort study of 71 biopsy‐proven cLN patients at Beijing Children's Hospital (2005–2024). Renal biopsies were classified per 2018 ISN/RPS criteria with activity index (AI) and chronicity index (CI) assessment.
Results
Over a median 40‐month follow‐up, 69.1% were female (mean onset age 10.0 ± 2.3 years). Proliferative LN (Class III/IV ± V) accounted for 76.0%. AI correlated with acute injury markers (creatinine, BUN, proteinuria); CI showed stronger associations with chronic tubular biomarkers but not eGFR. Complete renal remission (CRR) was achieved in 92.8% (mean 13.4 months); 26.6% experienced relapse. Failure to achieve CRR was associated with higher AI (OR = 1.738, p = 0.045), elevated SLEDAI‐2K (OR = 1.339, p = 0.023), and lower C3 (OR = 0.002, p = 0.035). Higher CI predicted lower likelihood of achieving LLDAS (OR = 1.425, p = 0.042). Belimumab reduced relapse risk (OR = 0.220, p = 0.043), decreased glucocorticoid doses (8.42 vs. 16.54 mg/day, p = 0.034), and improved LLDAS (68.4% vs. 30.0%, p = 0.006) and clinical remission rates (52.6% vs. 20.0%, p = 0.016). CKD developed in 4.3%; mortality was 1.4%.
Conclusion
Modern treatment yields favorable outcomes for cLN. Baseline disease activity, hypocomplementemia, and histological AI predict treatment response. AI and CI demonstrate distinct associations with acute and chronic injury. Belimumab offers significant advantages in relapse prevention and glucocorticoid reduction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
ORCID-Profile: Shi-Peng Li, Feng-Qiao Gao, Jun-Mei Zhang, Xuan-Yi Liu, Cai-Feng Li
Zitieren
APA
Sun, B. X., Li, S. P., Gao, F. Q., Liu, S., Zhao, W., Zhang, J. M., Tan, X. H., Li, C., Liu, X. Y., & Li, C. F. (2026). Clinicopathological Correlations, Treatment Response, and Predictors of Outcomes in Childhood Lupus Nephritis in China. International Journal of Rheumatic Diseases, 29(7). https://doi.org/10.1111/1756-185x.70774
Vancouver
Sun BX, Li SP, Gao FQ, Liu S, Zhao W, Zhang JM, et al. Clinicopathological Correlations, Treatment Response, and Predictors of Outcomes in Childhood Lupus Nephritis in China. International Journal of Rheumatic Diseases. 2026;29(7). doi:10.1111/1756-185x.70774
BibTeX
@article{Sun2026,
author = {Sun, Bai-Xu and Li, Shi-Peng and Gao, Feng-Qiao and Liu, Shuo and Zhao, Wei and Zhang, Jun-Mei and Tan, Xiao-Hua and Li, Chao and Liu, Xuan-Yi and Li, Cai-Feng},
title = {Clinicopathological Correlations, Treatment Response, and Predictors of Outcomes in Childhood Lupus Nephritis in China},
journal = {International Journal of Rheumatic Diseases},
year = {2026},
volume = {29},
number = {7},
doi = {10.1111/1756-185x.70774}
}
EUVIMED